























CRUK CENTRE FOR DRUG DEVELOPMENT

SMALL MOLECULES

AGENT/TRIAL	TARGET/TECHNOLOGY	PARTNER	INDICATIONS	FIRST IN HUMAN/ FIRST IN CLASS	DEVELOPMENT STAGE					
					PROJECT INITIATION	EXPLORATORY	PRE-CLINICAL	TRIAL SET UP	PHASE I/II	PHASE II
BT1718	MT1-MMP		Solid, lung	First in class (closed)	→					
HTL0039732	EP4		Solid, colorectal, prostate, gastric, oesophageal, renal	First in human	→					
LY3143921	Cdc7		Solid, colorectal, ovarian, lung	First in human (closed)	→					
TT702 (CURATE)	adenosine A _{2B} R		Solid	First in human	→					
DETERMINE - Alectinib - Dabrafenib/ Trametinib - Entrectinib	ALK, BRAF, MEK, ROS1, TKI, TRK	  	Rare adult, paediatric & TYA cancers	Phase II Phase II combination Phase II	→ → →					
DETERMINE - Capmatinib - Vemurafenib/ Cobimetinib	BRAF, cMET, HGFR, MAP, MEK	  	Rare adult cancers	Phase II Phase II combi (closed)	→ →					

CRUK CENTRE FOR DRUG DEVELOPMENT BIOLOGICS

AGENT/TRIAL	TARGET/ TECHNOLOGY	PARTNER	INDICATIONS	FIRST IN HUMAN/ FIRST IN CLASS	DEVELOPMENT STAGE					
					PROJECT INITIATION	EXPLORAT- ORY	PRE- CLINICAL	TRIAL SET UP	PHASE I/II	PHASE II
NVG222 solid	BITE ROR1, CD3	 NOVALGEN	Solid	First in indication	→					
ALETA001	Protein CD19, CD20	 ALETA BIOTHERAPEUTICS	Lymphoma	First in class	→					
HMBD001	Antibody Her3	 Hummingbird Bioscience	Solid, prostate	First in human (closed)	→					
KJ103	Antibody TROP2	 木曾 印路 Kisoji	Solid, breast, lung, renal, oral	First in class	→					
NVG222 haematological	BITE ROR1, CD3	 NOVALGEN	Lymphoma	First in human	→					
UCB4594	Antibody HLA-G1	 ucb	Solid, renal	First in human	→					
VTP600 (MAGE)	Vaccine MAGE3, NY-ESO-1	 BARINTHUS BIO PHARMACEUTICALS	Lung	First in human (closed)	→					
CY101	Peptide β-catenin, WNT	 cytovation NORWEGIAN CANCER SOCIETY	Adenocortical carcinoma	First in class Phase II	→					
DETERMINE - Atezolizumab - Trastuzumab/ Pertuzumab	Antibodies PDL1 HER2	 MANCHESTER 1824 The University of Manchester  Roche	Rare adult, paediatric & TYA cancers	Phase II Phase II combination	→					
Ginisortamab (UCB6114)	Antibody Gremlin1	 ucb  NORWEGIAN CANCER SOCIETY	Pancreatic	First in class Phase II	→					